Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,442.00GBp
25 Jun 2019
Change (% chg)

-- (--)
Prev Close
6,442.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,161,145
52-wk High
6,545.00
52-wk Low
5,110.00

Latest Key Developments (Source: Significant Developments)

Astrazeneca And Merck's Lynparza Approved In Japan
Wednesday, 19 Jun 2019 

June 19 (Reuters) - Merck & Co Inc ::ASTRAZENECA AND MERCK’S LYNPARZA® (OLAPARIB) APPROVED IN JAPAN AS FIRST-LINE MAINTENANCE THERAPY IN PATIENTS WITH BRCA-MUTATED ADVANCED OVARIAN CANCER.MERCK & CO - JAPAN'S PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA) HAS APPROVED LYNPARZA AS A MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY.MERCK & CO INC - LYNPARZA APPROVAL IN JAPAN WAS BASED ON DATA FROM RANDOMIZED, DOUBLE-BLINDED PHASE 3 SOLO-1 TRIAL.  Full Article

Astrazeneca Says Breztri Aerosphere (PT010) Approved In Japan For Patients With Chronic Obstructive Pulmonary Disease
Wednesday, 19 Jun 2019 

June 19 (Reuters) - AstraZeneca PLC ::BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.  Full Article

Astrazeneca Says Lynparza Approved In Japan For 1st-Line Maintenance Therapy In Brca-Mutated Advanced Ovarian Cancer
Wednesday, 19 Jun 2019 

June 19 (Reuters) - AstraZeneca PLC ::LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVANCED OVARIAN CANCER.  Full Article

Astrazeneca Says Bevespi Aerosphere Approved By Japanese Ministry Of Health, Labour And Welfare
Wednesday, 19 Jun 2019 

June 19 (Reuters) - AstraZeneca PLC ::BEVESPI AEROSPHERE APPROVED BY JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.  Full Article

Astrazeneca Says Lokelma Presented Positive Results From Phase IIIb Dialize Trial
Friday, 14 Jun 2019 

June 14 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC - LOKELMA DEMONSTRATED EFFICACY IN TREATING HYPERKALAEMIA IN PATIENTS WITH ENDSTAGE RENAL DISEASE ON HAEMODIALYSIS.ASTRAZENECA - IN PHASE IIIB DIALIZE TRIAL, 41.2% OF LOKELMA PATIENTS MAINTAINED NORMAL POTASSIUM LEVELS PRE-DIALYSIS VERSUS 1% RECEIVING PLACEBO.ASTRAZENECA PLC - SAFETY PROFILE OF LOKELMA OBSERVED IN DIALIZE WAS CONSISTENT WITH PREVIOUS TRIALS.ASTRAZENECA - PRESENTED POSITIVE RESULTS FROM PHASE IIIB DIALIZE TRIAL.  Full Article

Astrazeneca Says Calquence Phase III Elevate-TN Trial Met Primary Endpoint
Thursday, 6 Jun 2019 

June 6 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC - CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARY.ASTRAZENECA - CALQUENCE ALONE OR IN COMBINATION SIGNIFICANTLY INCREASED TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION.ASTRAZENECA PLC - TRIAL ALSO MET A KEY SECONDARY ENDPOINT SHOWING CALQUENCE MONOTHERAPY ACHIEVED A STATISTICALLY-SIGNIFICANT.ASTRAZENECA PLC - TRIAL'S SAFETY AND TOLERABILITY OF CALQUENCE WAS CONSISTENT WITH ITS ESTABLISHED PROFILE.  Full Article

Astrazeneca Plots Search For Next Chairman - Sky News
Monday, 3 Jun 2019 

June 3 (Reuters) - :ASTRAZENECA PLOTS SEARCH FOR NEXT CHAIRMAN - SKY NEWS.ASTRAZENECA BOARD IS AT EARLY STAGES OF PLANNING TO SEEK EVENTUAL REPLACEMENT FOR LEIF JOHANSSON, WHO HAS CHAIRED CO FOR 7 YEARS- SKY NEWS.  Full Article

Sensei Biotherapeutics Announces Clinical Trial Collaboration Agreement With Astrazeneca For Two Phase 2 Studies Of SNS-301
Tuesday, 7 May 2019 

May 7 (Reuters) - AstraZeneca PLC ::SENSEI BIOTHERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION AGREEMENT WITH ASTRAZENECA FOR TWO PHASE 2 STUDIES OF SNS-301.SENSEI BIOTHERAPEUTICS- ASTRAZENECA AND SENSEI WILL COLLABORATE TO EVALUATE COMBINATION OF SNS-301 AND IMFINZI.SENSEI BIOTHERAPEUTICS- ASTRAZENECA WILL SUPPLY IMFINZI FOR CLINICAL STUDIES & SENSEI WILL SPONSOR AND FUND PHASE 2 STUDIES.SENSEI BIOTHERAPEUTICS - ASTRAZENECA AND SENSEI WILL EACH RETAIN FULL WORLDWIDE RIGHTS TO THEIR RESPECTIVE MOLECULES.  Full Article

Transgene And Astrazeneca Announce Collaboration For Invir.IO Based Armed Oncolytic Immunotherapies
Thursday, 2 May 2019 

May 2 (Reuters) - TRANSGENE SA ::TRANSGENE AND ASTRAZENECA ENTER INTO A COLLABORATION AND EXCLUSIVE LICENSE OPTION AGREEMENT FOR INNOVATIVE INVIR.IOTM BASED ARMED ONCOLYTIC IMMUNOTHERAPIES.TRANSGENE AND ASTRAZENECA ENTER INTO A COLLABORATION AND EXCLUSIVE LICENSE OPTION AGREEMENT FOR INNOVATIVE INVIR.IOTM BASED ARMED ONCOLYTIC IMMUNOTHERAPIES.5 NOVEL ONCOLYTIC IMMUNOTHERAPIES WILL BE DEVELOPED BASED ON TRANSGENE'S NEW INVIR.IO(TM) PLATFORM.TRANSGENE TO RECEIVE $10 MILLION UPON SIGNING AND IS ELIGIBLE TO RECEIVE FURTHER DEVELOPMENT MILESTONE PAYMENTS AND ROYALTIES.TRANSGENE IS TO RECEIVE ADDITIONAL PRE-CLINICAL SUCCESS MILESTONES OF UP TO $3 MILLION.  Full Article

AstraZeneca starts AI collaboration to accelerate drug discovery
Tuesday, 30 Apr 2019 

April 30 (Reuters) - AstraZeneca PLC ::ASTRAZENECA - CO, BENEVOLENTAI BEGAN COLLABORATION TO USE AI FOR DISCOVERY & DEVELOPMENT OF NEW TREATMENTS FOR CHRONIC KIDNEY DISEASE.ASTRAZENECA - CO, BENEVOLENTAI BEGAN COLLABORATION TO USE AI FOR DISCOVERY & DEVELOPMENT OF NEW TREATMENTS FOR IDIOPATHIC PULMONARY FIBROSIS.  Full Article

Photo

FTSE 100 steady, Sino-U.S. trade talks back in focus

London's main index edged up on Monday as gains in defensive stocks such as healthcare were balanced by pressure on Asia-focussed banks, with Sino-U.S. trade talks once again set to take centre stage at this week's G20 summit.